Open access
Open access
Powered by Google Translator Translator

Cardio-oncology

Review | Interventional cardio-oncology: unique challenges and considerations in a high-risk population

8 Aug, 2023 | 13:27h | UTC

Interventional Cardio-Oncology: Unique Challenges and Considerations in a High-Risk Population – Current Treatment Options in Oncology

 


Review | Guiding the use of invasive cardiac interventions in patients with advanced malignancies

17 Jul, 2023 | 13:23h | UTC

Invasive Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: A Conceptual Framework: JACC: CardioOncology State-of-the-Art Review – JACC: CardioOncology

 


Review | How to treat diffuse large B-cell lymphoma: oncologic and cardiovascular considerations

26 Jun, 2023 | 00:33h | UTC

How to Treat Diffuse Large B-Cell Lymphoma: Oncologic and Cardiovascular Considerations – JACC: CardioOncology

 

Commentary on Twitter

 


Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies

1 Jun, 2023 | 11:48h | UTC

Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies – Blood Cancer Journal

 


RCT | Statins do not prevent early cardiac dysfunction in anthracycline-treated cancer patients

15 May, 2023 | 13:07h | UTC

Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines – European Heart Journal – Cardiovascular Pharmacotherapy (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Cohort Study | Outcomes of surgery in cardiac angiosarcoma

12 May, 2023 | 13:35h | UTC

Outcomes of Surgery in Cardiac Angiosarcoma: A Multi-Institutional Study From the National Cancer Database – JACC: CardioOncology

 

Commentary on Twitter

 


Atrial fibrillation incidence associated with exposure to anticancer drugs used as monotherapy in clinical trials

10 May, 2023 | 15:54h | UTC

Atrial Fibrillation Incidence Associated With Exposure to Anticancer Drugs Used as Monotherapy in Clinical Trials – JACC: CardioOncology

Editorials:

Atrial Fibrillation With Modern Cancer Treatment: More Common Than We Think – JACC: CardioOncology

Atrial Fibrillation in Patients With Cancer: A Persistent and Increasing Challenge – JACC: CardioOncology

 

Commentary on Twitter

 


RCT | Ibrutinib plus rituximab improve CLL PFS vs chemoimmunotherapy, but increased unexplained/cardiac deaths

8 May, 2023 | 13:00h | UTC

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial – The Lancet Oncology

 


Cohort Study | Ibrutinib is associated with increased cardiovascular events and major bleeding in older CLL patients

8 May, 2023 | 12:59h | UTC

Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL Patients – JACC: CardioOncology

 

Commentary on Twitter

 


Review | Cancer treatment-related cardiovascular toxicity in gynecologic malignancies

26 Apr, 2023 | 14:14h | UTC

Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies: JACC: CardioOncology State-of-the-Art Review – JACC: CardioOncology

 

Commentary on Twitter

 


Cohort Study | Incident cardiovascular events and imaging phenotypes in UK Biobank participants with past cancer

26 Apr, 2023 | 14:05h | UTC

Incident cardiovascular events and imaging phenotypes in UK Biobank participants with past cancer – Heart

News Release: Previous cancer linked to long term heightened risk of CVD – BMJ Newsroom

 


Cardiovascular disease in testicular cancer survivors: Identification of risk factors and impact on quality of life

25 Apr, 2023 | 14:34h | UTC

Cardiovascular Disease in Testicular Cancer Survivors: Identification of Risk Factors and Impact on Quality of Life – Journal of Clinical Oncology

 


Cohort Study | Risk of cancer after diagnosis of cardiovascular disease

25 Apr, 2023 | 14:29h | UTC

Risk of Cancer After Diagnosis of Cardiovascular Disease – CardioOncology

Commentary: New details on the link between CVD and cancer, from a study of 27M patients – Cardiovascular Business

 


Outcomes of ST elevation myocardial infarction in patients with cancer: a nationwide study

27 Mar, 2023 | 13:12h | UTC

Outcomes of ST elevation myocardial infarction in patients with cancer: a nationwide study – European Heart Journal – Quality of Care and Clinical Outcomes (free for a limited period)

 

Commentary on Twitter

 


Retrospective Cohort | Arrhythmogenic cardiotoxicity associated with contemporary treatments of lymphoproliferative disorders

14 Mar, 2023 | 13:27h | UTC

Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders – Journal of the American Heart Association

 


Cardiovascular disease related to immune therapy: JACC: CardioOncology special focus issue

28 Feb, 2023 | 13:37h | UTC

Cardiovascular Disease Related to Immune Therapy: JACC: CardioOncology Special Focus Issue – JACC: CardioOncology

Homepage: Special Focus Issue: Immune Therapy

Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review

Cancer Immunotherapy Beyond Checkpoint Blockade: JACC: CardioOncology State-of-the-Art Review

Atherosclerosis With Immune Checkpoint Inhibitor Therapy: Evidence, Diagnosis, and Management: JACC: CardioOncology State-of-the-Art Review

Cardiotoxicity of T-Cell Antineoplastic Therapies: JACC: CardioOncology Primer

What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?

The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity

Related:

Cardiovascular complications of immune checkpoint inhibitors for cancer – European Heart Journal

Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute—Cancer Therapy Evaluation Program – Journal of Clinical Oncology

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment – Journal of the American Heart Association

Cardiotoxicity of immune checkpoint inhibitors – ESMO Open

Cardiotoxicity from immune checkpoint inhibitors – IJC Heart & Vasculature

Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology – Journal of the Formosan Medical Association

Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock – JACC: CardioOncology

 


Case-control study | Association of anthracycline with heart failure in patients treated for breast cancer or lymphoma, 1985-2010

6 Feb, 2023 | 13:20h | UTC

Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010 – JAMA Network Open

Invited Commentary: Heart Failure in Patients With Cancer Treated With Anthracyclines—Revisiting the Foundation of Cardio-Oncology- JAMA Network Open

 

Commentary on Twitter

 


Consensus Paper | Cardio-oncology recommendations for pediatric oncology patients

31 Jan, 2023 | 13:54h | UTC

Cardio-Oncology Recommendations for Pediatric Oncology Patients: An Australian and New Zealand Delphi Consensus – JACC: Advances

News Release: International guidelines to help prevent and treat heart complications in pediatric oncology patients – Murdoch Childrens Research Institute/News Medical

 


Pre-existing autoimmune disease increases the risk of cardiovascular and noncardiovascular events after immunotherapy

26 Jan, 2023 | 12:09h | UTC

Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy – JACC: CardioOncology

Commentary: Preexisting Autoimmune Disease and Risk for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy for Cancer – The ASCO Post

 


Cohort Study | Biomarker trends, incidence, and outcomes of immune checkpoint inhibitor–induced myocarditis

24 Jan, 2023 | 14:16h | UTC

Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor–Induced Myocarditis – JACC: CardioOncology

Editorial: Biomarkers for Immune Checkpoint Inhibitor–Induced Myocarditis: Caution Needed – JACC: CardioOncology

News Release: New biomarker strategy devised to screen for, diagnose deadly heart complication from cancer treatment – University of Michigan

Commentary: Biomarker Trends of Immune Checkpoint Inhibitor–Induced Myocarditis – American College of Cardiology

 

Commentary from the author on Twitter

 


AHA Statement | Cancer therapy-related hypertension

23 Jan, 2023 | 13:46h | UTC

Cancer Therapy–Related Hypertension: A Scientific Statement From the American Heart Association – Hypertension

Top Things to Know: Cancer Therapy-Related HTN – American Heart Association

Commentary: Cancer and hypertension induced by anticancer drugs: The need for increased awareness, improved detection and proactive management – American Heart Association

 


The year in cardiovascular medicine 2022: the top 10 papers in cardio-oncology

9 Jan, 2023 | 14:08h | UTC

The year in cardiovascular medicine 2022: the top 10 papers in cardio-oncology – European Heart Journal

 

Commentary on Twitter

 


Consensus Paper | Evaluation and management of cancer patients presenting with acute cardiovascular diseases.

9 Dec, 2022 | 13:28h | UTC

Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Clinical Consensus Statement of the Acute CardioVascular Care Association (ACVC) and the ESC council of Cardio-Oncology—part 2: acute heart failure, acute myocardial diseases, acute venous thromboembolic diseases, and acute arrhythmias – European Heart Journal. Acute Cardiovascular Care

See also: Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology—Part 1: acute coronary syndromes and acute pericardial diseases – European Heart Journal. Acute Cardiovascular Care

Related:

The ‘Ten Commandments’ for the 2022 European Society of Cardiology guidelines on cardio-oncology.

#ESCCongress | 2022 ESC Guidelines on cardio-oncology.

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations – Annals of Oncology

Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement from the American Heart Association – Circulation

Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline

Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations – Revista Espanola de Cardiologia

Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology—Part 1: acute coronary syndromes and acute pericardial diseases – European Heart Journal. Acute Cardiovascular Care

Brazilian Cardio-oncology Guideline – 2020 – Arquivos Brasileiros de Cardiologia

AHA Statement: Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors

 


Review | AL Amyloidosis for Cardiologists.

6 Dec, 2022 | 13:36h | UTC

AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review – JACC: CardioOncology

 


The ‘Ten Commandments’ for the 2022 European Society of Cardiology guidelines on cardio-oncology.

29 Nov, 2022 | 14:13h | UTC

The ‘Ten Commandments’ for the 2022 European Society of Cardiology guidelines on cardio-oncology – European Journal of Cardiology

Original guideline: #ESCCongress | 2022 ESC Guidelines on cardio-oncology.

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.